Short Interest in Pharvaris N.V. (NASDAQ:PHVS) Drops By 17.4%

Pharvaris N.V. (NASDAQ:PHVS) saw a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 746,902 shares, a decrease of 17.4% from the January 15th total of 904,318 shares. Based on an average daily trading volume, of 150,463 shares, the days-to-cover ratio is presently 5.0 days. Based on an average daily trading volume, of 150,463 shares, the days-to-cover ratio is presently 5.0 days.

Analysts Set New Price Targets

PHVS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research note on Wednesday, December 3rd. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, November 19th. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Guggenheim boosted their target price on Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Finally, Leerink Partners set a $38.00 price target on Pharvaris in a research note on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $40.56.

Pharvaris Trading Down 0.6%

Shares of NASDAQ PHVS traded down $0.15 during mid-day trading on Monday, hitting $26.45. 92,452 shares of the stock traded hands, compared to its average volume of 128,811. Pharvaris has a 52 week low of $11.51 and a 52 week high of $29.80. The stock has a fifty day moving average price of $26.06 and a 200-day moving average price of $24.32.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PHVS. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. HighVista Strategies LLC raised its stake in Pharvaris by 4.3% during the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after buying an additional 971 shares during the last quarter. California State Teachers Retirement System raised its stake in Pharvaris by 9.8% during the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock valued at $247,000 after buying an additional 1,257 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Pharvaris in the fourth quarter worth $35,000. Finally, Legal & General Group Plc grew its stake in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.